Title : When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.

Pub. Date : 2020 Oct

PMID : 32814685






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The PARP inhibitors olaparib and rucaparib are now FDA approved for mCRPC patients with HRR mutations and BRCA1/2 mutations, respectively. rucaparib BRCA1 DNA repair associated Homo sapiens